Supreme Court of the United States · Official docket →
Vaxima, Inc., et al. v. United States
Paid petition · United States Court of Appeals for the Fourth Circuit, No. 17-4277, 17-4278 · judgment February 28, 2022
Before the decision, roughly the 4.1% base rate. The model weighted this up for counsel with five or more prior petitions here, a business petitioner, and a Fourth Circuit decision below.
Questions presented
-
Whether a criminal forfeiture judgment against Petitioners Vaxima, Inc. and GenPhar, Inc. (collectively “Petitioners”) under 28 U.S.C. § 2461(c), is permitted under this Court’s decision in Honeycutt v. United States, 137 S. Ct. 1626 (2017) (“Honeycutt”).
-
Whether a criminal conviction can be supported by an indictment alleging that Petitioners’ conduct amounted to breach of contract.
Counsel of record
For petitioner
Robert Edward Barnes
Barnes law
For respondent
Elizabeth B. Prelogar
Solicitor General
Case
Subject area
Criminal Procedure (estimated from the questions presented, in the Supreme Court Database’s categories)
Conference history
Distributed for 1 conference
Proceedings
- Oct 03 2022Petition DENIED.
- Jul 20 2022DISTRIBUTED for Conference of 9/28/2022.
- Jul 13 2022Waiver of right of respondent United States to respond filed.
- Jun 25 2022Petition for a writ of certiorari filed. (Response due August 5, 2022)